Lake Street Capital Issues Pessimistic Forecast for TELA Bio (NASDAQ:TELA) Stock Price

TELA Bio (NASDAQ:TELA) had its price objective lowered by stock analysts at Lake Street Capital from $3.00 to $2.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s price target suggests a potential upside of 184.09% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Loop Capital set a $3.00 price objective on shares of TELA Bio in a research note on Monday, December 1st. Canaccord Genuity Group dropped their price target on shares of TELA Bio from $4.00 to $2.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TELA Bio in a report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $2.65.

TELA Bio Stock Performance

Shares of NASDAQ:TELA traded down $0.06 during trading on Wednesday, hitting $0.70. 211,109 shares of the stock were exchanged, compared to its average volume of 173,705. The company has a market capitalization of $28.40 million, a price-to-earnings ratio of -0.79 and a beta of 0.88. The company has a debt-to-equity ratio of 26.65, a quick ratio of 2.62 and a current ratio of 3.30. TELA Bio has a 1-year low of $0.67 and a 1-year high of $2.20. The company’s fifty day simple moving average is $0.85 and its 200-day simple moving average is $1.14.

TELA Bio (NASDAQ:TELA) last issued its earnings results on Tuesday, March 24th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. TELA Bio had a negative return on equity of 272.13% and a negative net margin of 50.61%.The firm had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $21.04 million. Sell-side analysts expect that TELA Bio will post -1.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of TELA. WealthTrust Axiom LLC acquired a new position in TELA Bio during the 2nd quarter worth $40,000. XTX Topco Ltd bought a new position in TELA Bio in the 4th quarter valued at $48,000. Citadel Advisors LLC increased its stake in shares of TELA Bio by 161.3% in the 3rd quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock valued at $53,000 after buying an additional 21,781 shares during the period. Susquehanna International Group LLP raised its position in shares of TELA Bio by 551.2% during the third quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock worth $128,000 after acquiring an additional 72,594 shares during the last quarter. Finally, Embree Financial Group raised its position in shares of TELA Bio by 695.1% during the fourth quarter. Embree Financial Group now owns 111,318 shares of the company’s stock worth $131,000 after acquiring an additional 97,318 shares during the last quarter. Institutional investors own 94.35% of the company’s stock.

TELA Bio News Summary

Here are the key news stories impacting TELA Bio this week:

• Positive Sentiment: Reported EPS slightly beat consensus and showed improvement vs. last year; the company delivered record revenue growth language in its results, supporting the bullish case on recovery and execution. Earnings Release / Transcript
• Positive Sentiment: Management is targeting at least 8% revenue growth for 2026 and says it is advancing a commercial transformation, which, if delivered, could support a rebound in sales momentum. Seeking Alpha — Growth Target
• Neutral Sentiment: Full earnings call and transcripts are available for investors who want details on sales trends, margin drivers and the commercial plan — useful for judging execution risk. Earnings Call Transcript
• Neutral Sentiment: Short?interest reports in recent feeds show inconsistent/zero values, indicating data noise rather than a clear change in short positioning; treat these figures with caution.
• Negative Sentiment: Revenue for the quarter came in slightly below consensus ($20.87M reported vs. $21.04M expected), and the company still shows a negative net margin and steep ROE swing — factors pressuring near?term profitability expectations. Zacks — Q4 Results
• Negative Sentiment: Canaccord cut its price target from $4.00 to $2.00 (still a “buy”), which reduces analyst-implied upside and likely dampens sentiment despite the maintained rating. Benzinga — Price Target Cut

TELA Bio Company Profile

TELA Bio, Inc (NASDAQ: TELA) is a commercial?stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.